When combined with bevacizumab, the Vasgene mAbs 131 and 47 elicit tumour shrinkage in xenograft models via the degradation of EphB4, blocking tumour vasculature and slowing tumour progression [127]. The gene discussed is EPHB4; the disease is neoplasm.